Newsletter – Mid-Game Investment Category (Vol. 1, No. 4)

The World Class R&D InstituteMid-Game (Investment Category+)

 We continue the description of Investment Categories by discussing mid-game. These are the Investible Units+ where we have already placed our bets. How do we track their progress? How do we ensure they are as successful as can be?

July 2010 Home Page

subscribe iconhome page image thumb


Last month we introduced the four main R&D investment categories (i.e., pre-game+, mid-game, end-game+ and commercialization+). This month we discuss mid-game: deciding whether or not to continue funding of R&D investments already underway. We do this without relying on cheap heuristics+, portfolio optimization or other ineffective practices seen frequently in industrial R&D. We discuss the role of Independent Evaluation+, the 5 P’s, and the many support structures we put in place to help good leaders become great.

Next month we take a short break from investment categories, and discuss a topic that has become urgent for many of our colleagues in research: Protecting R&D from the buffeting winds of the corporation. How do we protect research, which can take decades, from very frequent changes in corporate direction and priorities? Does this strike a chord? Here's a starter list of protections needed by R&D. Register and vote for those you consider to be the most important. We preview this topic with an article on the use of Franchise Fees as a means to counteract damages inflicted by arbitrary cost-cutting measures.

There are 15 new articles this month. One is perhaps more thought-provoking than the others. Free Market R&D illustrates the huge challenge we face as we move away from a paternalistic, overly-bureaucratic model of industrial R&D, and toward an entrepreneurial, free-market approach. This leads in turn to thinking on how to undermine today’s entrenched interests in order to advance toward a World Class R&D capability. To be continued.

Finally I include a transcript of the very short (10 minute) introduction I gave last month at the Drug Information Association (DIA) panel discussion on mini-clini’s. Frequent readers of this website will recognize the arguments.

Wishing you and yours a very fruitful summer holiday.


Keith Ortiz
President and CEO
The World Class R&D Institute, A Non-Profit Institution
609-954-8319 (c)

If you would like to be removed from the mailing list for this periodic update, reply to this e-mail stating so and I’ll make it happen.

Browse Newsletter Summaries